This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cancer Patients Aren't Responding to Northwest Bio's DCVax-Direct

By: Adam Feuerstein | 05/27/14 - 06:07 PM EDT

(Updated from May  27 at 6:07 pm ET)

The tumor response rate attributable to Northwest Biotherapeutics (NWBO) DCVax-Direct is zero. None of the 19 patients with advanced, metastatic cancers have responded to treatment with DCVax-Direct in an ongoing phase I clinical study.

Perhaps you're confused by Northwest Bio's glowingly positive DCVax-Direct press release issued Tuesday morning, or CEO Linda Power's conference call after Tuesday's market close in which she reiterated how well desperately sick cancer patients were responding to the company's magical dendritic cell soup

Well, you only have to let Powers speak for 20 minutes or so before the truth comes dribbling out. On her conference call, Powers acknowledges the best response seen so far following DCVax-Direct injections directly into a single tumor was 28% shrinkage. Under the globally accepted definition of tumor response known as RECIST (Response Evaluation Criteria in Solid Tumors), a partial response requires a 30% reduction in the size of the target lesion. 

DCVax-Direct: 0% response rate. 

Keep spinning, Linda! There are more cancer patients with little hope who need to be exploited. The "Naysayers" will always be here to unpack the truth.

Wednesday update: Powers, on last night's conference call, conjured up a false and misleading comparison between DCVax-Direct and the cancer immunotherapy "checkpoint inhibitors" being developed by Bristol-Myers Squibb (BMY), Merck (MRK) and other large drug companies. I'm paraphrasing her words, but Powers claims the 50% response rate observed in the DC-Vax Direct phase I study to date is greater than the 25% response rates seen when checkpoint inhibitors are used as monotherapy, and even better than the 40% response rates for checkpoint inhibitor combination therapy. 

Excuse my language, but Powers is spewing bullshit. Bristol's nivolumab and Merck's MK-3475 have shown to be remarkably effective at shrinking tumors and prolonging survival in patients with advanced melanoma, lung cancer and other solid tumors as both monotherapy and in combinations. I've already written about some of the checkpoint inhibitor data which will be presented in more detail at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. Over the weekend and on Monday, even more impressive results from these drugs will be announced.

For Powers to compare the unconfirmed, anecdotal  and faux responses to DCVax-Direct to the real and profound efficacy seen from checkpoint inhibitors is completely irresponsible and absurd. But like most of her actions, Powers' motivation is stock promotion, not helping cancer patients. Northwest Bio would rather issue press releases and hold conference calls for ignorant retail investors than present real clinical data at a respected medical meeting like ASCO. Northwest Bio didn't submit any of its DCVAX-Direct data for peer review and presentation at ASCO. Instead, the company bought a booth in the exhibition hall, where it can give away free pens to anyone who happens to walk by.



Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs